



13-08-2012

To,
The Manager, Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza"
Bandra-Kurla Complex,
Bandra – East,
Mumbai

Sub: Unaudited Financial Results for the Quarter ended 30th June, 2012

Dear Sir,

With reference to the captioned matter, the Unaudited Financial Results for the Quarter ended 30th June, 2012, duly reviewed by the statutory auditors and approved by Board of the Company at its meeting held today are enclosed herewith.

Please take the same on your record.

Thanking you,

For Alembic Limited

Chirag K. Shukla
Company Secretary

ALEMBIC LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA-390 003. • TEL. : (0265) 2280660, 2280880 • FAX : (0265) 2282506
www.alembic-india.com • E-mail : alembic@alembic.co.in

An ISO 9002 & ISO 14001 Company



ALEMBIC LIMITED

Regd. Office: Alembic Road, Vadodra 392 003

UNAUDITED FINANCIAL RESULTS

FOR THE QUARTER ENDED 30TH JUNE, 2012

		₹ in Lacs			
	Particulars	Quarter Ended on 30th June 2012	Quarter Ended on 31st March 2012	Quarter Ended on 30th June 2011	Year Ended on 31st March 2012
PART- I					
1	(a) Net Sales / Income from Operations				
	Domestic	2,613	2,334	3,790	11,704
	Exports	188	122	456	940
	Total	2,801	2,456	4,246	12,644
	Less : Excise Duty	267	243	320	1,042
	Net Sales / Income from Operations	2,534	2,213	3,926	11,602
	(b) Other Operating Income	78	1	29	84
	Total Income from Operations	2,612	2,214	3,955	11,686
2	Expenses				
	(a) Decrease/(Increase) in stock in trade and work in progress	375	(337)	(1,059)	(2,445)
	(b) Consumption of Raw Materials & Packing Materials	995	1,161	3,151	7,774
	(c) Purchase of traded goods	-	-	-	-
	(d) Employees' Cost	577	379	507	2,551
	(e) Excise Duty	(80)	52	103	151
	(f) Other Expenditure	999	1,076	879	4,192
	Total Expenses	2,866	2,292	3,661	12,223
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	(254)	(68)	294	(537)
4	Dividend Income	-	-	-	565
5	Other Income	161	113	72	471
6	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	(93)	45	366	499
7	Depreciation	248	257	375	1,093
8	Interest (Net)	89	133	136	520
9	Net Profit / (Loss) from Ordinary Activities before Exceptional Items	(430)	(345)	(95)	(1,114)
10	Exceptional Items - Voluntary Retirement Scheme	-	-	239	248
11	Net Profit / (Loss) from Ordinary Activities before Tax	(430)	(345)	(334)	(1,361)
12	Tax Expense				
	Less : Provision for Current / Wealth Tax	-	-	-	-
	Less/(Add) : Provision for Deferred Tax Liability/(Assets)	(37)	(36)	(47)	(142)
	Less/(Add) : Provision of Income Tax of earlier years written back (Net)	-	-	-	-
13	Net Profit / (Loss) from Ordinary Activities after Tax	(393)	(302)	(287)	(1,219)
14	Paid up Equity Share Capital (Face value of share ₹ 2/-)	2,670	2,670	2,670	2,670
15	Reserves excluding Revaluation Reserve	-	-	-	5,014
16	Basic & Diluted EPS (Not Annualised)	(0.29)	(0.73)	(0.21)	(0.91)
PART- II					
A	Particulars of Shareholding				
1	Public Shareholding				
	- Number of Shares	48777294	48777294	48763089	48777294
	- Percentage of Shareholding	36.53	36.53	36.52	36.53
2	Promoters and Promoter Group Shareholding				
	- Fully Non - Encumbered				
	- Number of Shares	84738620	84738620	84752820	84738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	Percentage of Shares (as a % of the total share capital of the Company)	63.47	63.47	63.48	63.47
B	INVESTOR COMPLAINTS	Quarter ended on 30th June, 2012			
	Pending at the beginning of the quarter	NIL			
	Received during the quarter	NIL			
	Disposed of during the quarter	NIL			
	Remaining unresolved at the end of the quarter	NIL			



Notes :

- 1 The above results have been duly reviewed by Statutory Auditors, were recommended by the Audit Committee and were approved by the Board of Directors.
- 2 The Company has started a real estate project for residential use. The project is in initial stage and no revenue / profit is recognised in the current quarter / period and therefore, the Company has reported only pharmaceutical segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 3 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- 4 There was lack of Government support for levying anti-dumping duty despite efforts of the company. Hence, the company has stopped the production of "Penicillin - G" as imports from China have resulted in unviable prices. The company is in process of exploring other alternative options to utilize its manufacturing capacity.



Place : Vadodara
Date : 13th Aug, 2012



For Alembic Limited

Chirayu Amin
Chairman

K. S. AIYAR & CO
CHARTERED ACCOUNTANTS


F-7 Laxmi Mills
Shakti Mills Lane (Off. Dr E. Moses Rd)
Mahalaxmi Mumbai 400 011 India
Tel : 91 22 2493 2502 / 6655 1770
Fax : 91 22 6655 1774
Grams : VERIFY
www.KSAiyar.com
Mail@KSAiyar.com

To,
The Board of Directors;
Alembic Limited;
Alembic Road, Vadodara.

RE: **LIMITED REVIEW OF THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED
30th June, 2012.**

1. We have reviewed the accompanying statement of unaudited financial results of Alembic Limited for the quarter ended on 30th June, 2012 attached herewith except for the disclosures regarding public shareholding and Promoter and Promoter Group shareholding which have been traced from disclosures made by the management and have not been audited by us. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to express a conclusion on this interim financial information based on our review. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors.
2. We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.S.Aiyar & Co.
Chartered Accountants
FRN: 100186W


Rajesh S. Joshi
Partner
M.No. 38526

Place: Vadodara
Date: 13th August, 2012

Offices also at
Chennai Kolkata Goa
Bangalore Coimbatore